India’s drug regulator has issued an alert regarding the theft of several batches of injectable medicines belonging to Novo Nordisk during transit.
According to a notice issued by the Drugs Controller General of India (DCGI), Dr. Rajeev Raghuvanshi, “Novo Nordisk has reported a theft of its products, as listed below, during transit from its Bhiwandi hub to distribution routes covering Nagpur, Raipur, Cuttack, and Kolkata.”
The DCGI further cautioned that the stolen products are temperature-sensitive and must be stored at 2°C to 8°C. Improper storage could compromise the quality and safety of these medicines.
The notice stated: “The products under consideration are rDNA-origin injectables that require storage at 2°C to 8°C. If these products are not handled under proper storage conditions, their quality may be adversely affected, which in turn could pose serious risks to patient safety. The matter is currently under police investigation.”
The stolen products include:
1. Insulin degludec/Insulin aspart (rDNA origin) solution for injection – Ryzodeg FlexTouch (Batch No. RT6GY9G)
2. Insulin aspart (rDNA origin) solution for injection – Fiasp Penfill® (Batch No. RR726A8)
3. Insulin aspart (rDNA origin) solution for injection – Fiasp FlexTouch® (Batch No. RP5P640)
4. Semaglutide Injection 0.5 mg (rDNA origin) – Wegovy FlexTouch® (Batch No. RP5S233)
5. Semaglutide Injection 0.25 mg (rDNA origin) – Wegovy FlexTouch® (Batch No. RP5S232)
6. Semaglutide Injection 1 mg (rDNA origin) – Wegovy FlexTouch (Batch No. RP5S210)
Doctors and healthcare professionals have been advised to exercise caution while prescribing these products and to educate patients about reporting any adverse drug reactions (ADRs). Patients and consumers have been urged to procure these medicines only from authorized sources with a valid invoice.
The DCGI has circulated this notice to all State and Union Territory Drugs Controllers, as well as to Zonal and Sub-Zonal offices of the Central Drugs Standard Control Organization (CDSCO).
